Back to Search
Start Over
A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
- Source :
-
Current medicinal chemistry [Curr Med Chem] 2019; Vol. 26 (30), pp. 5625-5648. - Publication Year :
- 2019
-
Abstract
- Alzheimer's Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Subjects :
- Acetylcholinesterase metabolism
Alzheimer Disease metabolism
Animals
Butyrylcholinesterase metabolism
Cholinesterase Inhibitors chemistry
Donepezil chemistry
Humans
Molecular Structure
Neuroprotective Agents chemistry
Alzheimer Disease drug therapy
Cholinesterase Inhibitors pharmacology
Cholinesterase Inhibitors therapeutic use
Donepezil pharmacology
Donepezil therapeutic use
Neuroprotective Agents pharmacology
Neuroprotective Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1875-533X
- Volume :
- 26
- Issue :
- 30
- Database :
- MEDLINE
- Journal :
- Current medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 29768996
- Full Text :
- https://doi.org/10.2174/0929867325666180517094023